Kathy Lenhard is the Chief Executive Officer and founder of PanAmerican Clinical Research, applying her more than 30 years of experience in supporting the development needs of global pharmaceutical, vaccine, and medical device companies.

Under her leadership PanAmerican has grown to support phase I-IV research in all indications and throughout South, Central, and North America. From its inception, Kathy installed a culture and business model that extends beyond CRO services and empowers limited-resource areas with health education, screening, and resources, ultimately partnering clinical research and public health to build healthier communities.

Before PanAmerican, Kathy held a number of high level clinical operations positions running large complex clinical trials in multiple therapeutic areas, in every region of the world, and in the most challenging environments. Notably, Kathy led the 2009 Novavax clinical study in the epicenter of the H1N1 Pandemic in Mexico City, which is published in Vaccine Journal (Vaccine 29 (2011) 7826-7834).

More recently, Kathy served as the Project Lead for the Bill & Melinda Gates Foundation studies in the area of Neglected Tropical Disease and presented the project to the World Health Organization in Geneva Switzerland in 2016. Kathy is active in giving back to the research community and is a frequent speaker and educator on clinical research. She is also the author of “Regulated Clinical Research,” an accredited graduate course in Mexico.